NCT04827004 - A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Trial Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing